A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
Study Details
Study Description
Brief Summary
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
In this Phase 3, double-blind, randomized, vehicle-controlled, parallel-group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been met. Male and female participants at least 18 years of age with moderate or severe papulopustular rosacea will be eligible for enrollment for daily treatment with S5G4T-1 or its vehicle for 12 weeks.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: S5G4T-1 Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks. |
Drug: S5G4T-1
Once a day topical cream
Other Names:
|
Placebo Comparator: S5G4T-2 Vehicle Cream Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks. |
Drug: S5G4T-2
Once a day topical cream
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 [Baseline through Week 12]
Percentage of participants in each treatment group achieving an acne severity IGA score of "clear (score=0)" or "almost clear (score=1)". Please note, the Percentage of Participants multiplied by the Overall Number of Participants Analyzed does not equal a whole number because missing efficacy data was based on estimation using the method of Markov Chain Monte Carlo (MCMC) imputation.
- Change From Baseline in Inflammatory Lesion Counts at Week 12 [Baseline, Week 12]
Inflammatory lesions were characterized as papules and pustules. A papule was defined as a solid, elevated inflammatory lesion equal to or less than 5 mm in diameter. A pustule was defined as an elevated inflammatory lesion equal to or less than 5 mm in diameter and contains pus (yellow-white exudate). Least squares means and standard deviations from an analysis of covariance (ANCOVA) with factors of treatment, analysis center and treatment by analysis center interaction and the Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.
Secondary Outcome Measures
- Percent Change From Baseline in Inflammatory Lesion Counts at Week 12 [Baseline, Week 12]
Inflammatory lesions were characterized as papules and pustules. A papule was defined as a solid, elevated inflammatory lesion equal to or less than 5 mm in diameter. A pustule was defined as an elevated inflammatory lesion equal to or less than 5 mm in diameter and contains pus (yellow-white exudate). Least squares means and standard deviations from an ANCOVA with factors of treatment and analysis center and Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study.
-
Male and female 18 years of age and older.
-
Participants must have clinical diagnosis of moderate to severe rosacea.
-
Have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose.
-
Have 2 nodules or less.
Exclusion Criteria:
-
Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at Baseline or screening visits.
-
Presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm).
-
Current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sol-Gel | Rochester | New York | United States | 14623 |
Sponsors and Collaborators
- Sol-Gel Technologies, Ltd.
Investigators
None specified.Study Documents (Full-Text)
More Information
Publications
None provided.- SGT-54-02
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail | Participants were randomized to receive either S5G4T-1 (Encapsulated Benzoyl Peroxide [E-BPO] cream) or vehicle in a 2:1 ratio. |
Arm/Group Title | S5G4T-1 | S5G4T-2 Vehicle Cream |
---|---|---|
Arm/Group Description | Participants topically applied S5G4T-1 cream, once daily to face for 12 weeks. | Participants topically applied S5G4T-2 vehicle cream, once daily to face for 12 weeks. |
Period Title: Overall Study | ||
STARTED | 250 | 122 |
Received at Least 1 Dose of Study Drug | 249 | 120 |
COMPLETED | 235 | 113 |
NOT COMPLETED | 15 | 9 |
Baseline Characteristics
Arm/Group Title | S5G4T-1 | S5G4T-2 Vehicle Cream | Total |
---|---|---|---|
Arm/Group Description | Participants topically applied S5G4T-1 cream, once daily to face for 12 weeks. | Participants topically applied S5G4T-2 vehicle cream, once daily to face for 12 weeks. | Total of all reporting groups |
Overall Participants | 250 | 122 | 372 |
Age (Years) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Years] |
49.5
(14.04)
|
51.5
(12.55)
|
50.1
(13.59)
|
Sex: Female, Male (Count of Participants) | |||
Female |
181
72.4%
|
87
71.3%
|
268
72%
|
Male |
69
27.6%
|
35
28.7%
|
104
28%
|
Ethnicity (NIH/OMB) (Count of Participants) | |||
Hispanic or Latino |
55
22%
|
30
24.6%
|
85
22.8%
|
Not Hispanic or Latino |
195
78%
|
92
75.4%
|
287
77.2%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Race (NIH/OMB) (Count of Participants) | |||
American Indian or Alaska Native |
0
0%
|
2
1.6%
|
2
0.5%
|
Asian |
20
8%
|
8
6.6%
|
28
7.5%
|
Native Hawaiian or Other Pacific Islander |
3
1.2%
|
2
1.6%
|
5
1.3%
|
Black or African American |
2
0.8%
|
0
0%
|
2
0.5%
|
White |
220
88%
|
110
90.2%
|
330
88.7%
|
More than one race |
5
2%
|
0
0%
|
5
1.3%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Baseline Inflammatory Lesion Count (Lesions) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [Lesions] |
29.8
(14.00)
|
27.5
(13.04)
|
29.0
(13.72)
|
Baseline Investigator's Global Assessment (IGA) (participants) [Number] | |||
0 - Clear |
0
0%
|
0
0%
|
0
0%
|
1 - Almost Clear |
0
0%
|
0
0%
|
0
0%
|
2 - Mild |
0
0%
|
0
0%
|
0
0%
|
3 - Moderate |
227
90.8%
|
112
91.8%
|
339
91.1%
|
4 - Severe |
23
9.2%
|
10
8.2%
|
33
8.9%
|
Outcome Measures
Title | Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 |
---|---|
Description | Percentage of participants in each treatment group achieving an acne severity IGA score of "clear (score=0)" or "almost clear (score=1)". Please note, the Percentage of Participants multiplied by the Overall Number of Participants Analyzed does not equal a whole number because missing efficacy data was based on estimation using the method of Markov Chain Monte Carlo (MCMC) imputation. |
Time Frame | Baseline through Week 12 |
Outcome Measure Data
Analysis Population Description |
---|
The ITT population consisted of all randomized participants who were dispensed study drug. MCMC was used to impute missing values. |
Arm/Group Title | S5G4T-1 | S5G4T-2 Vehicle Cream |
---|---|---|
Arm/Group Description | Participants topically applied S5G4T-1 cream, once daily to face for 12 weeks. | Participants topically applied S5G4T-2 vehicle cream, once daily to face for 12 weeks. |
Measure Participants | 250 | 122 |
Number [Percentage of Participants] |
50.1
20%
|
25.9
21.2%
|
Title | Change From Baseline in Inflammatory Lesion Counts at Week 12 |
---|---|
Description | Inflammatory lesions were characterized as papules and pustules. A papule was defined as a solid, elevated inflammatory lesion equal to or less than 5 mm in diameter. A pustule was defined as an elevated inflammatory lesion equal to or less than 5 mm in diameter and contains pus (yellow-white exudate). Least squares means and standard deviations from an analysis of covariance (ANCOVA) with factors of treatment, analysis center and treatment by analysis center interaction and the Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline. |
Time Frame | Baseline, Week 12 |
Outcome Measure Data
Analysis Population Description |
---|
The ITT population consisted of all randomized participants who were dispensed study drug. MCMC was used to impute missing values. |
Arm/Group Title | S5G4T-1 | S5G4T-2 Vehicle Cream |
---|---|---|
Arm/Group Description | Participants topically applied S5G4T-1 cream, once daily to face for 12 weeks. | Participants topically applied S5G4T-2 vehicle cream, once daily to face for 12 weeks. |
Measure Participants | 250 | 122 |
Least Squares Mean (Standard Deviation) [Inflammatory Lesions] |
-20.3
(9.64)
|
-13.3
(9.60)
|
Title | Percent Change From Baseline in Inflammatory Lesion Counts at Week 12 |
---|---|
Description | Inflammatory lesions were characterized as papules and pustules. A papule was defined as a solid, elevated inflammatory lesion equal to or less than 5 mm in diameter. A pustule was defined as an elevated inflammatory lesion equal to or less than 5 mm in diameter and contains pus (yellow-white exudate). Least squares means and standard deviations from an ANCOVA with factors of treatment and analysis center and Baseline lesion count as a covariate. Negative least squares means values represent decrease from Baseline. |
Time Frame | Baseline, Week 12 |
Outcome Measure Data
Analysis Population Description |
---|
The ITT population consisted of all randomized participants who were dispensed study drug. MCMC was used to impute missing values. |
Arm/Group Title | S5G4T-1 | S5G4T-2 Vehicle Cream |
---|---|---|
Arm/Group Description | Participants topically applied S5G4T-1 cream, once daily to face for 12 weeks. | Participants topically applied S5G4T-2 vehicle cream, once daily to face for 12 weeks. |
Measure Participants | 250 | 122 |
Least Squares Mean (Standard Deviation) [Percent Change] |
-69.4
(32.66)
|
-46.0
(32.31)
|
Adverse Events
Time Frame | Baseline (Day 0) through end of study (Week 12) | |||
---|---|---|---|---|
Adverse Event Reporting Description | Safety population included randomized participants who were presumed to have used the study drug at least once and who provided at least 1 post-baseline safety evaluation. The total number of participants in the safety population differs from the Participant Flow because one participant who was randomized to E-BPO Cream actually received Vehicle Cream. The safety analyses counted this participant in the Vehicle Cream group since participants were analyzed based on actual study drug received. | |||
Arm/Group Title | S5G4T-1 | S5G4T-2 Vehicle Cream | ||
Arm/Group Description | Participants topically applied S5G4T-1 cream, once daily to face for 12 weeks. | Participants topically applied S5G4T-2 vehicle cream, once daily to face for 12 weeks. | ||
All Cause Mortality |
||||
S5G4T-1 | S5G4T-2 Vehicle Cream | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/248 (0%) | 0/121 (0%) | ||
Serious Adverse Events |
||||
S5G4T-1 | S5G4T-2 Vehicle Cream | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 1/248 (0.4%) | 0/121 (0%) | ||
Injury, poisoning and procedural complications | ||||
Spinal compression fracture | 1/248 (0.4%) | 0/121 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
S5G4T-1 | S5G4T-2 Vehicle Cream | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 13/248 (5.2%) | 12/121 (9.9%) | ||
General disorders | ||||
Application site pain | 6/248 (2.4%) | 0/121 (0%) | ||
Application site erythema | 3/248 (1.2%) | 0/121 (0%) | ||
Application site pruritus | 3/248 (1.2%) | 0/121 (0%) | ||
Infections and infestations | ||||
Nasopharyngitis | 6/248 (2.4%) | 3/121 (2.5%) | ||
Sinusitis | 3/248 (1.2%) | 0/121 (0%) | ||
Urinary tract infection | 2/248 (0.8%) | 3/121 (2.5%) | ||
Influenza | 2/248 (0.8%) | 2/121 (1.7%) | ||
Upper respiratory tract infection | 2/248 (0.8%) | 2/121 (1.7%) | ||
Respiratory, thoracic and mediastinal disorders | ||||
Sinus congestion | 1/248 (0.4%) | 2/121 (1.7%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
Generally, the Principal Investigator is not permitted to discuss or publish trial results without Sponsor approval.
Results Point of Contact
Name/Title | Sol-Gel |
---|---|
Organization | Sol-Gel Technologies, Ltd. |
Phone | 972-8-9313433 |
info@sol-gel.com |
- SGT-54-02